Answers are grounded in this paper and cite their sources.
Craniofacial and periodontal defects collectively impose one of the largest tissue-loss burdens in regenerative medicine. They span a broad spectrum of etiologies chronic periodontitis to acute maxillofacial trauma. The field has shifted from biomaterial and cell-based strategies that minimize host inflammation toward strategies that orchestrate it. This review synthesizes the current evidence base for immune modulation in craniofacial and periodontal regeneration and frames it around a central thesis: successful regeneration depends on the timed transition from an early inflammatory phase that clears microbes and recruits progenitors to a pro-resolution phase that supports angiogenesis, osteogenesis, cementogenesis, and periodontal ligament reattachment. In this review, we explore unique features of the oral and craniofacial niche, including scarless mucosal wound-healing phenotype, contributions of saliva and gingival crevicular fluid, and resident immune populations that maintain tolerance to a dense commensal microbiome. In addition, we examine the temporal logic of innate immunity from neutrophil and monocyte infiltration through macrophage M1-to-M2 transition, alongside adaptive contributions from regulatory T cells, T helper 17 cells, and antibody-mediated responses. Then, osteoimmunology is examined in the context of neural crest-derived craniofacial bone and the periodontal ligament as an immunomodulatory niche. Four immunomodulatory intervention classes are reviewed: scaffold-based design, controlled release of cytokines, ions, and specialized pro-resolving mediators, mesenchymal stromal cell and extracellular vesicle therapies, and direct macrophage or regulatory T cell engineering. Translational barriers and future directions pave the way for the convergence of immunology, biomaterials science, and clinical dentistry toward an emerging discipline of niche immunoengineering for the craniofacial complex.Impact StatementCraniofacial and periodontal regeneration carries a global burden exceeding one billion prevalent cases yet remains poorly served by regeneration paradigms imported from long bone or skin. This review consolidates the case that immune orchestration, rather than immune suppression, is the central lever for regenerative success in this niche. By organizing the evidence into a coherent framework of biomaterial, molecular, cellular, and immune-engineering strategies, the review offers clinicians, immunologists, and tissue engineers a shared vocabulary for designing and evaluating immune-informed regenerative therapies with realistic prospects for clinical translation.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: